Meihua Dingchang Completes Nearly RMB 100 Million Series B Financing to Advance Innovative Long-Acting Microsphere Injection Technology Platform

VCBeat has learned that Zhejiang Meihua Dingchang Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “MHDC”) recently announced the completion of its Series B financing round, raising nearly RMB 100 million. The round was led by Paradise Silicon Valley, with participation from Shulan Junjie Capital, Hangzhou Liyuan Venture Capital Co., Ltd., and other investors. The funds will be primarily used to advance the construction of MHDC’s GMP-compliant production line for innovative long-acting injectable microspheres, thereby facilitating the clinical trial applications of multiple products in development, including several Class 1 and Class 2 new drugs.

Previously, MHDC completed its tens-of-millions-of-yuan Series A financing round in September 2018, exclusively led by Oriental Fortune Capital.

MHDC, established in 2011, is a pharmaceutical R&D company driven by advanced drug delivery technologies.One of the founders of MHDC is Dr. Wang Chuanyue, who previously served as a drug R&D scientist at Wyeth and TEVA Pharmaceuticals, bringing extensive experience in pharmaceutical analysis and the development of complex, high-difficulty sustained- and controlled-release formulations. Furthermore, the core technical team comprises experts with rich experience in polymer materials, medicinal chemistry, and clinical medicine, dedicated to building MHDC into a leading dual-platform enterprise in China that specializes in the R&D of innovative long-acting microsomal injectables and complex sustained- and controlled-release formulations.

“Ten years of honing a single sword,” MHDC has long been dedicated to drug R&D focused on advanced drug delivery technologies. The company has now largely completed the establishment of its two core technology platforms, achieving breakthroughs in high drug-loading with minimal burst release, scalable manufacturing, and highly reproducible preparation processes. It is now poised to advance clinical trial applications with the NMPA and FDA.

MHDC’s pipeline of long-acting injectable microsphere products covers indications such as type 2 diabetes, periodontitis, and recurrent/refractory fungal infections, further improving patients’ clinical benefits through optimized routes of administration and dosage forms.

Meanwhile, MHDC is actively positioning itself in the field of highly complex modified-release formulations. Several products will enter the market through dual filings in China and the United States. One innovative medical device has already obtained US FDA 510(k) clearance and is poised to launch sales in the US market shortly.

In the future, MHDC will continue to focus on the R&D of innovative microsphere injectable products as its core business, and establish an innovative microsphere injectable technology platform compliant with international cGMP standards., committed to enhancing the safety, efficacy, and stability of clinical medication to benefit human health.

Tiantang Silicon Valley stated:MHDC, an outstanding pharmaceutical R&D enterprise incubated in Keqiao District, Shaoxing City, has long been under our close observation. The company is primarily composed of a team of overseas-educated PhDs, with its core team possessing extensive R&D experience in innovative long-acting microsphere injections and highly complex modified-release formulations. After ten years of development, the company has basically taken shape as a platform-based R&D enterprise specializing in innovative long-acting microsphere injections. It is poised to become one of the few domestic companies mastering key manufacturing processes for microsphere formulations and is expected to file clinical trial applications for multiple microsphere products. This investment in MHDC demonstrates Tiantang Silicon Valley’s alignment with the development trends of China’s healthcare industry, its strategic deep-dive into the high-barrier field of innovative drug formulations, and its commitment to accelerating the rapid development of domestic formulation innovation.

Shulan Junjie Capital stated:Against the backdrop of modified new drugs becoming a hotspot in R&D, MHDC has taken a pragmatic approach. Leveraging years of technological accumulation, it has gradually established a product pipeline featuring multiple candidates with significant clinical advantages and market differentiation. Following the completion of this financing round, while continuing to advance the registration or commercialization of existing products, the company is poised to leverage its advanced formulation technology platform to develop additional new pipelines, holding substantial prospects for future growth.

Hangzhou Liyuan Venture Capital Co., Ltd. stated:The MHDC team, founded by overseas returnees, has established its roots in Zhejiang and successfully built a drug controlled-release technology development platform. Several new drug R&D projects have achieved key breakthroughs, drawing significant attention from the industry. We believe this round of investment will accelerate the company’s capacity building and help propel it toward success.

Heavenly Silicon Valley Asset Management Group Co., Ltd. is one of the first private equity investment firms established in China. Founded on November 11, 2000, it was formed by six listed companies and their shareholders, including Heavenly Silicon Valley (833044) and Qianjiang Water Resources (600283), with a paid-in capital of RMB 1.2 billion. The Group has consistently adhered to the investment philosophy of “investors first, value investing, and industry focus,” specializing in two core business areas: equity investment and PIPE (Private Investment in Public Equity). It maintains a precise strategic focus on four key sectors: information technology, intelligent manufacturing, healthcare, and mass consumer goods.

To date, Paradise Silicon Valley has invested in more than 30 companies in the healthcare sector, among which 15 are either publicly listed or under regulatory review. These include B-Soft, Starry Pharmaceutical, Jinshi Asia Pharma, Shuangcheng Pharmaceutical, Jimin Pharmaceutical, TianGuangShi, Baicheng Medicine, and Soochow Biologics. Additionally, it has facilitated M&A incubation and transformation upgrades for listed companies such as Jingxin Pharmaceutical, Guangzheng Ophthalmology, and Tailong Pharmaceutical.

Shulan Junjie Capital was jointly established by early investors and the founding team of Shulan Healthcare Group. It serves the translation of medical technology innovations into industry on a global scale by leveraging clinical resources. By establishing technology investment funds, the SATOL Life Sciences Accelerator, and the SATOL Global Medical Innovation and Entrepreneurship Center, as well as hosting the World Life Sciences Conference and the Global Medical Innovation and Entrepreneurship Competition, it promotes the integrated development of clinical practice, scientific research, and industry through three core businesses: community services, fund investment, and research incubation. It supports the innovation and entrepreneurship of medical science and technology talents and has invested in a number of outstanding technology enterprises in fields such as digital diagnostics and treatment, biotechnology, and innovative therapies.

Hangzhou Liyuan Venture Capital Co., Ltd. was established in 2005 as one of the first professionally managed venture capital firms in China to operate on a market-oriented basis. Registered with the National Development and Reform Commission (NDRC) and qualified as a private fund manager, the company specializes in private equity (PE), venture capital (VC), angel investing, and fund management. Adhering to a prudent operational style, excelling in project risk control, and prioritizing profitability, Liyuan Venture Capital has invested in more than 200 companies, over 20 of which have successfully gone public.